Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by relentless cognitive decline. Despite decades of research dominated by the amyloid and tau hypotheses, clinical interventions targeting these classical hallmarks have yielded limited success in halting disease progression, underscoring a critical conceptual and therapeutic gap: the early, persistent, and under-addressed role of mitochondrial dysfunction as a primary driver of AD pathology. Beyond serving as pas